Exploration and metabolomics analysis procedure set up to gain insights into the differences between the first two-stage of non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL - stage 1), and non-alcoholic steatohepatitis (NASH), with the final goal being to find potential new biomarkers for better diagnosis and prognosis of the disease. By using LC-MS analysis to examine different compartments within patients (including portal vein blood, liver, and peripheral blood), I can depict a potential group of biomarkers (sphingolipids). Additionally, a pipeline was established for metabolomic profiling applied to different projects, including exploring the lipid changes in H.Pylori under treatment conditions and cancer pathological comparison. My future goal is to combine metabolomics with other omics analyses to understand how NAFLD develops and the stages for a better diagnosis and treatment.